Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim for prevention of chemotherapy-induced neutropenia in digestive tract cancer
ChiCTR2100052432Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in gastric cancer (GC) and intestinal cancer, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoints: Incidence of grade 3 and 4 neutropenia and Incidence and severity of all adverse events. Started Oct 2021; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
gastric cancer (GC)intestinal cancer
Beyond the preview
Go deeper on ChiCTR2100052432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052432.